Skip to content
Companies

Jupiter Biomedical Research

Small-molecule drugs for glioblastoma and viral infections

Raised to date

$500K

of $500K offered across 1 Form D filing

Investors
30
Last filed
May 5, 2026

About

Jupiter Biomedical Research is a preclinical-stage drug development company in Palm Beach Gardens, Florida, formed to commercialize two internally developed small-molecule candidates. Its lead oncology candidate, JBR-102, is a new chemical entity advanced through IND-enabling preclinical studies for glioblastoma multiforme, an aggressive brain cancer, with additional activity reported against prostate, lung and colon cancers, melanoma and blood cancers. Its second candidate, JBR-201, is an antiviral compound focused initially on measles and herpes virus strains. The company is not a contract research organization; it owns and develops its own therapeutic pipeline.

Two internally discovered new chemical entities rather than in-licensed assets, with JBR-102 reported to retain potency against tumor cells whether actively dividing or in the biosynthetic phases preceding cell division, and now being reformulated from intravenous to oral administration.

Funding

  • EquityFiled May 5, 2026Form D/A
    $500K/ $500K

Product

JBR-102

Preclinical oncology therapeutic

A new chemical entity advanced through preclinical, IND-enabling studies as a treatment for glioblastoma multiforme, originally formulated for intravenous delivery in late-stage GBM and being redesigned as an oral medication.

  • New chemical entity discovered in-house
  • Completed IND-enabling preclinical studies
  • Lead indication: glioblastoma multiforme (GBM)

Built for

Pharmaceutical licensees and, ultimately, neuro-oncologists and infectious disease clinicians treating patients with glioblastoma and viral infections

People on file